{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-109035","form_type":"8-K","ticker":"HCWB","cik":"0001828673","company_name":"HCW Biologics Inc.","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.183572+00:00","generated_at":"2026-05-17T13:23:13.537687+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"HCW Biologics Q2 net loss narrows to $1.9M; revenue drops 99%; going concern warning","bullets":["Q2 2025 net loss improved to $1.9M from $15.3M in Q2 2024; revenue fell to $6.6K from $618.9K.","Wugen license suspended for one year; company seeks new partner for HCW9206.","Raised $5.0M equity in May 2025; extinguished $6.9M debt via restructuring.","Company expresses substantial doubt about ability to continue as going concern for next 12 months.","On track to initiate Phase 1 trial for HCW9302 in autoimmune disorder in Q3 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-109035","json":"https://secwatch.observer/filing/0000950170-25-109035.json","markdown":"https://secwatch.observer/filing/0000950170-25-109035.md","text":"https://secwatch.observer/filing/0000950170-25-109035.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828673/000095017025109035/0000950170-25-109035-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828673/000095017025109035/hcwb-20250814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:23:13.537687+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}